Wolchok, Jedd D

Publications

Sort by

Co-Author Network

selected publications

Eganelisib, a First-in-Class PI3Kγ Inhibitor, in Patients with Advanced Solid Tumors: Results of the Phase 1/1b MARIO-1 Trial. Clinical cancer research : an official journal of the American Association for Cancer Research. 2023 Academic Article GET IT
MCT4-dependent lactate secretion suppresses antitumor immunity in LKB1-deficient lung adenocarcinoma. Cancer cell. 2023 Academic Article GET IT
RECISTv1.1 progression in oncology: Shades of gray. Cancer cell. 2023 Academic Article GET IT
Personalized RNA neoantigen vaccines stimulate T cells in pancreatic cancer. Nature. 2023 Academic Article GET IT
Times cited: 3
OX40L-expressing recombinant modified vaccinia virus Ankara induces potent antitumor immunity via reprogramming Tregs. The Journal of experimental medicine. 2023 Academic Article GET IT
Beyond the 5-year milestone: Long-term survivorship of melanoma patients treated off-trial with anti-PD-1. Pigment cell & melanoma research. 2023 Academic Article GET IT
Prior anti-CTLA-4 therapy impacts molecular characteristics associated with anti-PD-1 response in advanced melanoma. Cancer cell. 2023 Academic Article GET IT
Decision-Making and Health-Related Quality of Life in Patients with Melanoma Considering Adjuvant Immunotherapy. The oncologist. 2023 Academic Article GET IT
Times cited: 1
Genomic and transcriptomic analysis of checkpoint blockade response in advanced non-small cell lung cancer. Nature genetics. 2023 Academic Article GET IT
Lineage tracing reveals clonal progenitors and long-term persistence of tumor-specific T cells during immune checkpoint blockade. Cancer cell. 2023 Academic Article GET IT
Times cited: 1
T cell immunotherapies engage neutrophils to eliminate tumor antigen escape variants. Cell. 2023 Academic Article GET IT
Times cited: 3
Harnessing imaging tools to guide immunotherapy trials: summary from the National Cancer Institute Cancer Imaging Steering Committee workshop. The Lancet. Oncology. 2023 Review GET IT
Times cited: 1
Pilot Study of ONCOS-102 and Pembrolizumab: Remodeling of the Tumor Microenvironment and Clinical Outcomes in Anti-PD-1-Resistant Advanced Melanoma. Clinical cancer research : an official journal of the American Association for Cancer Research. 2023 Editorial Article GET IT
Times cited: 6
The ectonucleotidase CD39 identifies tumor-reactive CD8⁺ T cells predictive of immune checkpoint blockade efficacy in human lung cancer. Immunity. 2022 Academic Article GET IT
Times cited: 2
Heat-inactivated modified vaccinia virus Ankara boosts Th1 cellular and humoral immunity as a vaccine adjuvant. NPJ vaccines. 2022 Academic Article GET IT
Times cited: 16
Clinical implications of T cell exhaustion for cancer immunotherapy. Nature reviews. Clinical oncology. 2022 Review GET IT
Times cited: 46
Immune-Related Adverse Events Among COVID-19-Vaccinated Patients With Cancer Receiving Immune Checkpoint Blockade. Journal of the National Comprehensive Cancer Network : JNCCN. 2022 Academic Article GET IT
Times cited: 3
Combination Dabrafenib and Trametinib Versus Combination Nivolumab and Ipilimumab for Patients With Advanced BRAF-Mutant Melanoma: The DREAMseq Trial-ECOG-ACRIN EA6134. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2022 Academic Article GET IT
Times cited: 32
Increased p53 expression induced by APR-246 reprograms tumor-associated macrophages to augment immune checkpoint blockade. The Journal of clinical investigation. 2022 Academic Article GET IT
Phase IB Study of GITR Agonist Antibody TRX518 Singly and in Combination with Gemcitabine, Pembrolizumab, or Nivolumab in Patients with Advanced Solid Tumors. Clinical cancer research : an official journal of the American Association for Cancer Research. 2022 Academic Article GET IT
Times cited: 5
Calreticulin mutant myeloproliferative neoplasms induce MHC-I skewing, which can be overcome by an optimized peptide cancer vaccine. Science translational medicine. 2022 Academic Article GET IT
Times cited: 5
Author Correction: Fundamental immune-oncogenicity trade-offs define driver mutation fitness. Nature. 2022 Article GET IT
Times cited: 1
Pilot Trial of Arginine Deprivation Plus Nivolumab and Ipilimumab in Patients with Metastatic Uveal Melanoma. Cancers. 2022 Academic Article GET IT
Times cited: 359
Tumor-induced double positive T cells display distinct lineage commitment mechanisms and functions. The Journal of experimental medicine. 2022 Academic Article GET IT
Times cited: 3
Neoantigen quality predicts immunoediting in survivors of pancreatic cancer. Nature. 2022 Academic Article GET IT
Times cited: 29
Fundamental immune-oncogenicity trade-offs define driver mutation fitness. Nature. 2022 Academic Article GET IT
Times cited: 8
Proton Pump Inhibitor Use and Efficacy of Nivolumab and Ipilimumab in Advanced Melanoma. Cancers. 2022 Academic Article GET IT
Times cited: 2039
Neoantigen-specific CD8 T cell responses in the peripheral blood following PD-L1 blockade might predict therapy outcome in metastatic urothelial carcinoma. Nature communications. 2022 Academic Article GET IT
Times cited: 21
Anatomic position determines oncogenic specificity in melanoma. Nature. 2022 Academic Article GET IT
Times cited: 18
Reply to T. Olivier et al. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2022 Letter GET IT
Therapeutic antibody activation of the glucocorticoid-induced TNF receptor by a clustering mechanism. Science advances. 2022 Academic Article GET IT
Times cited: 4
Ipilimumab alone or in combination with nivolumab in patients with advanced melanoma who have progressed or relapsed on PD-1 blockade: clinical outcomes and translational biomarker analyses. Journal for immunotherapy of cancer. 2022 Academic Article GET IT
Times cited: 9
Adaptive Dosing of Nivolumab + Ipilimumab Immunotherapy Based Upon Early, Interim Radiographic Assessment in Advanced Melanoma (The ADAPT-IT Study). Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2021 Academic Article GET IT
Times cited: 15
In vivo optical imaging-guided targeted sampling for precise diagnosis and molecular pathology. Scientific reports. 2021 Academic Article GET IT
Times cited: 4
Long-Term Outcomes With Nivolumab Plus Ipilimumab or Nivolumab Alone Versus Ipilimumab in Patients With Advanced Melanoma. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2021 Academic Article GET IT
Times cited: 194
Isoform specific anti-TGFβ therapy enhances antitumor efficacy in mouse models of cancer. Communications biology. 2021 Academic Article GET IT
Times cited: 5
Efficacy and safety of vedolizumab and infliximab treatment for immune-mediated diarrhea and colitis in patients with cancer: a two-center observational study. Journal for immunotherapy of cancer. 2021 Academic Article GET IT
Times cited: 26
Treatment-free survival over extended follow-up of patients with advanced melanoma treated with immune checkpoint inhibitors in CheckMate 067. Journal for immunotherapy of cancer. 2021 Academic Article GET IT
Times cited: 5
Cyclophosphamide enhances the antitumor potency of GITR engagement by increasing oligoclonal cytotoxic T cell fitness. JCI insight. 2021 Academic Article GET IT
Times cited: 2
Checkpoint blockade: the end of the beginning. Nature reviews. Immunology. 2021 Academic Article GET IT
Times cited: 5
Risks and benefits of reinduction ipilimumab/nivolumab in melanoma patients previously treated with ipilimumab/nivolumab. Journal for immunotherapy of cancer. 2021 Review GET IT
Times cited: 2
Enhancing immunotherapy in cancer by targeting emerging immunomodulatory pathways. Nature reviews. Clinical oncology. 2021 Review GET IT
Times cited: 173
Long-term outcomes in patients with advanced melanoma who had initial stable disease with pembrolizumab in KEYNOTE-001 and KEYNOTE-006. European journal of cancer (Oxford, England : 1990). 2021 Academic Article GET IT
Times cited: 7
Elucidating mechanisms of antitumor immunity mediated by live oncolytic vaccinia and heat-inactivated vaccinia. Journal for immunotherapy of cancer. 2021 Academic Article GET IT
Times cited: 5
LAG-3 expression on peripheral blood cells identifies patients with poorer outcomes after immune checkpoint blockade. Science translational medicine. 2021 Academic Article GET IT
Times cited: 32
CD8-Targeted PET Imaging of Tumor-Infiltrating T Cells in Patients with Cancer: A Phase I First-in-Humans Study of ⁸⁹Zr-Df-IAB22M2C, a Radiolabeled Anti-CD8 Minibody. Journal of nuclear medicine : official publication, Society of Nuclear Medicine. 2021 Academic Article GET IT
Times cited: 38
TMB and Inflammatory Gene Expression Associated with Clinical Outcomes following Immunotherapy in Advanced Melanoma. Cancer immunology research. 2021 Academic Article GET IT
Times cited: 37
Evidence generation and reproducibility in cell and gene therapy research: A call to action. Molecular therapy. Methods & clinical development. 2021 Editorial Article GET IT
Times cited: 5
Reply to: Combining TNF blockade with immune checkpoint inhibitors in patients with cancer. Nature reviews. Rheumatology. 2021 Letter GET IT
Inherited PD-1 deficiency underlies tuberculosis and autoimmunity in a child. 2021 GET IT
Times cited: 42
Pharmacologic modulation of RNA splicing enhances anti-tumor immunity. Cell. 2021 Academic Article GET IT
Times cited: 69
Eradicating micrometastases with immune checkpoint blockade: Strike while the iron is hot. Cancer cell. 2021 Academic Article GET IT
Times cited: 11
Tim-4⁺ cavity-resident macrophages impair anti-tumor CD8⁺ T cell immunity. Cancer cell. 2021 Academic Article GET IT
Times cited: 61
Uptake of oxidized lipids by the scavenger receptor CD36 promotes lipid peroxidation and dysfunction in CD8⁺ T cells in tumors. Immunity. 2021 Academic Article GET IT
Times cited: 152
CD8⁺ T cells contribute to survival in patients with COVID-19 and hematologic cancer. Nature medicine. 2021 Academic Article GET IT
Times cited: 242
A phase 1 study of NY-ESO-1 vaccine + anti-CTLA4 antibody Ipilimumab (IPI) in patients with unresectable or metastatic melanoma. Oncoimmunology. 2021 Academic Article GET IT
Times cited: 9
TNF in the era of immune checkpoint inhibitors: friend or foe?. Nature reviews. Rheumatology. 2021 Review GET IT
Times cited: 56
CTLA-4 blockade drives loss of T_reg stability in glycolysis-low tumours. Nature. 2021 Academic Article GET IT
Times cited: 130
CD8 T cells compensate for impaired humoral immunity in COVID-19 patients with hematologic cancer. Research square. 2021 Article GET IT
Times cited: 34
Therapeutic Implications of Detecting MAPK-Activating Alterations in Cutaneous and Unknown Primary Melanomas. Clinical cancer research : an official journal of the American Association for Cancer Research. 2021 Academic Article GET IT
Times cited: 15
Targeting Phosphatidylserine Enhances the Anti-tumor Response to Tumor-Directed Radiation Therapy in a Preclinical Model of Melanoma. Cell reports. 2021 Academic Article GET IT
Times cited: 14
Checkpoint Blockade in Melanoma Patients With Underlying Chronic Lymphocytic Leukemia. Journal of immunotherapy (Hagerstown, Md. : 1997). 2021 Academic Article GET IT
Times cited: 3
Metastasis and Immune Evasion from Extracellular cGAMP Hydrolysis. Cancer discovery. 2020 Academic Article GET IT
Times cited: 77
Long-term safety of pembrolizumab monotherapy and relationship with clinical outcome: A landmark analysis in patients with advanced melanoma. European journal of cancer (Oxford, England : 1990). 2020 Academic Article GET IT
Times cited: 40
Conserved Interferon-γ Signaling Drives Clinical Response to Immune Checkpoint Blockade Therapy in Melanoma. Cancer cell. 2020 Article GET IT
Times cited: 13
PD-L1 Blockade Therapy: Location, Location, Location. Cancer cell. 2020 Comment GET IT
Times cited: 8
Immigration in science. The Journal of experimental medicine. 2020 Academic Article GET IT
Times cited: 1
Conserved Interferon-γ Signaling Drives Clinical Response to Immune Checkpoint Blockade Therapy in Melanoma. Cancer cell. 2020 Academic Article GET IT
Times cited: 144
Blockade of the AHR restricts a Treg-macrophage suppressive axis induced by L-Kynurenine. Nature communications. 2020 Academic Article GET IT
Times cited: 131
Progressive choroidal thinning (leptochoroid) and fundus depigmentation associated with checkpoint inhibitors. 2020 GET IT
Times cited: 8
Determinants of COVID-19 disease severity in patients with cancer. Nature medicine. 2020 Academic Article GET IT
Times cited: 395
Immune Checkpoint Inhibitors for Cancer Therapy in the COVID-19 Era. Clinical cancer research : an official journal of the American Association for Cancer Research. 2020 Academic Article GET IT
Times cited: 30
Genome-wide cell-free DNA mutational integration enables ultra-sensitive cancer monitoring. Nature medicine. 2020 Academic Article GET IT
Times cited: 124
The many faces of the anti-COVID immune response. The Journal of experimental medicine. 2020 Academic Article GET IT
Times cited: 365
The future of cancer immunotherapy: microenvironment-targeting combinations. Cell research. 2020 Academic Article GET IT
Times cited: 345
Impact of PD-1 Blockade on Severity of COVID-19 in Patients with Lung Cancers. Cancer discovery. 2020 Academic Article GET IT
Times cited: 173
Determinants of Severity in Cancer Patients with COVID-19 Illness. medRxiv : the preprint server for health sciences. 2020 Article GET IT
A Prospective, Phase 1 Trial of Nivolumab, Ipilimumab, and Radiotherapy in Patients with Advanced Melanoma. Clinical cancer research : an official journal of the American Association for Cancer Research. 2020 Academic Article GET IT
Times cited: 16
Quality of life in long-term survivors of advanced melanoma treated with checkpoint inhibitors. Journal for immunotherapy of cancer. 2020 Academic Article GET IT
Times cited: 24
ILC2s amplify PD-1 blockade by activating tissue-specific cancer immunity. Nature. 2020 Academic Article GET IT
Times cited: 188
CD36-mediated metabolic adaptation supports regulatory T cell survival and function in tumors. Nature immunology. 2020 Academic Article GET IT
Times cited: 242
Long-Term Outcomes and Responses to Retreatment in Patients With Melanoma Treated With PD-1 Blockade. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2020 Academic Article GET IT
Times cited: 108
Absolute lymphocyte count as a prognostic biomarker for overall survival in patients with advanced melanoma treated with ipilimumab. Melanoma research. 2020 Academic Article GET IT
Times cited: 20
Safety of Inactivated Influenza Vaccine in Cancer Patients Receiving Immune Checkpoint Inhibitors. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America. 2020 Academic Article GET IT
Times cited: 70
Survival Outcomes After Metastasectomy in Melanoma Patients Categorized by Response to Checkpoint Blockade. Annals of surgical oncology. 2019 Academic Article GET IT
Times cited: 28
Author Correction: PD-1 blockade in subprimed CD8 cells induces dysfunctional PD-1⁺CD38^hi cells and anti-PD-1 resistance. Nature immunology. 2019 Article GET IT
Times cited: 4
First-in-Humans Imaging with ⁸⁹Zr-Df-IAB22M2C Anti-CD8 Minibody in Patients with Solid Malignancies: Preliminary Pharmacokinetics, Biodistribution, and Lesion Targeting. Journal of nuclear medicine : official publication, Society of Nuclear Medicine. 2019 Academic Article GET IT
Times cited: 131
Five-Year Survival and Correlates Among Patients With Advanced Melanoma, Renal Cell Carcinoma, or Non-Small Cell Lung Cancer Treated With Nivolumab. JAMA oncology. 2019 Academic Article GET IT
Times cited: 303
Five-Year Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma. The New England journal of medicine. 2019 Academic Article GET IT
Times cited: 1858
Intravitreous Cutaneous Metastatic Melanoma in the Era of Checkpoint Inhibition: Unmasking and Masquerading. Ophthalmology. 2019 Academic Article GET IT
Times cited: 16
Selective inhibition of low-affinity memory CD8⁺ T cells by corticosteroids. The Journal of experimental medicine. 2019 Academic Article GET IT
Times cited: 60
Recruit or Reboot? How Does Anti-PD-1 Therapy Change Tumor-Infiltrating Lymphocytes?. Cancer cell. 2019 Comment GET IT
Times cited: 19
Treatment-Free Survival: A Novel Outcome Measure of the Effects of Immune Checkpoint Inhibition-A Pooled Analysis of Patients With Advanced Melanoma. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2019 Academic Article GET IT
Times cited: 43
Opposing Functions of Interferon Coordinate Adaptive and Innate Immune Responses to Cancer Immune Checkpoint Blockade. Cell. 2019 Academic Article GET IT
Times cited: 205
Adjuvant ipilimumab versus placebo after complete resection of stage III melanoma: long-term follow-up results of the European Organisation for Research and Treatment of Cancer 18071 double-blind phase 3 randomised trial. European journal of cancer (Oxford, England : 1990). 2019 Academic Article GET IT
Times cited: 102
PD-1 blockade in subprimed CD8 cells induces dysfunctional PD-1⁺CD38^hi cells and anti-PD-1 resistance. Nature immunology. 2019 Academic Article GET IT
Times cited: 169
In situ vaccination with defined factors overcomes T cell exhaustion in distant tumors. The Journal of clinical investigation. 2019 Academic Article GET IT
Times cited: 28
Rational design of anti-GITR-based combination immunotherapy. Nature medicine. 2019 Academic Article GET IT
Times cited: 137
Pulsatile MEK Inhibition Improves Anti-tumor Immunity and T Cell Function in Murine Kras Mutant Lung Cancer. Cell reports. 2019 Academic Article GET IT
Times cited: 36
Analysis of the Prevalence of Microsatellite Instability in Prostate Cancer and Response to Immune Checkpoint Blockade. JAMA oncology. 2019 Academic Article GET IT
Times cited: 335
Five-year survival outcomes for patients with advanced melanoma treated with pembrolizumab in KEYNOTE-001. Annals of oncology : official journal of the European Society for Medical Oncology. 2019 Academic Article GET IT
Times cited: 496
Immunotherapy of Melanoma: Facts and Hopes. Clinical cancer research : an official journal of the American Association for Cancer Research. 2019 Review GET IT
Times cited: 144
Potentiating vascular-targeted photodynamic therapy through CSF-1R modulation of myeloid cells in a preclinical model of prostate cancer. Oncoimmunology. 2019 Academic Article GET IT
Times cited: 11
Myocarditis Surveillance in Patients with Advanced Melanoma on Combination Immune Checkpoint Inhibitor Therapy: The Memorial Sloan Kettering Cancer Center Experience. The oncologist. 2019 Letter GET IT
Times cited: 22
Adverse events 2.0-Let us get SERIOs: New reporting for adverse event outcomes needed in the era of immunooncology. European journal of cancer (Oxford, England : 1990). 2019 Letter GET IT
Times cited: 13
Correction to: Strategies for Predicting Response to Checkpoint Inhibitors. Current hematologic malignancy reports. 2019 Article GET IT
Tumor mutational load predicts survival after immunotherapy across multiple cancer types. Nature genetics. 2019 Academic Article GET IT
Times cited: 1996
Addressing current challenges and future directions in immuno-oncology: expert perspectives from the 2017 NIBIT Foundation Think Tank, Siena, Italy. Cancer immunology, immunotherapy : CII. 2018 Conference Paper GET IT
Times cited: 6
Correction: Baseline Tumor Size Is an Independent Prognostic Factor for Overall Survival in Patients with Melanoma Treated with Pembrolizumab. Clinical cancer research : an official journal of the American Association for Cancer Research. 2018 Academic Article GET IT
Times cited: 12
Putting the Immunologic Brakes on Cancer. Cell. 2018 Review GET IT
Times cited: 61
Prognostic value of baseline metabolic tumor volume measured on ¹⁸F-fluorodeoxyglucose positron emission tomography/computed tomography in melanoma patients treated with ipilimumab therapy. European journal of nuclear medicine and molecular imaging. 2018 Academic Article GET IT
Times cited: 64
Acquired resistance to immunotherapy in MMR-D pancreatic cancer. 2018 GET IT
Times cited: 27
¹⁸F-FDG PET/CT for Monitoring of Ipilimumab Therapy in Patients with Metastatic Melanoma. Journal of nuclear medicine : official publication, Society of Nuclear Medicine. 2018 Academic Article GET IT
Times cited: 102
Nivolumab plus ipilimumab or nivolumab alone versus ipilimumab alone in advanced melanoma (CheckMate 067): 4-year outcomes of a multicentre, randomised, phase 3 trial. The Lancet. Oncology. 2018 Academic Article GET IT
Times cited: 897
An Antitumor Immune Response Is Evoked by Partial-Volume Single-Dose Radiation in 2 Murine Models. International journal of radiation oncology, biology, physics. 2018 Academic Article GET IT
Times cited: 46
Emerging Concepts for Immune Checkpoint Blockade-Based Combination Therapies. Cancer cell. 2018 Academic Article GET IT
Times cited: 44
Non-conventional Inhibitory CD4⁺Foxp3^-PD-1^hi T Cells as a Biomarker of Immune Checkpoint Blockade Activity. Cancer cell. 2018 Academic Article GET IT
Times cited: 11
PD-L1 in tumor microenvironment mediates resistance to oncolytic immunotherapy. The Journal of clinical investigation. 2018 Academic Article GET IT
Times cited: 18
Strategies for Predicting Response to Checkpoint Inhibitors. Current hematologic malignancy reports. 2018 Review GET IT
Times cited: 21
The hallmarks of successful anticancer immunotherapy. Science translational medicine. 2018 Review GET IT
Times cited: 348
Refusing to TAP out: 16 new human TEIPPs identified. The Journal of experimental medicine. 2018 Comment GET IT
Pathologic features of response to neoadjuvant anti-PD-1 in resected non-small-cell lung carcinoma: a proposal for quantitative immune-related pathologic response criteria (irPRC). Annals of oncology : official journal of the European Society for Medical Oncology. 2018 Academic Article GET IT
Times cited: 228
MHC proteins confer differential sensitivity to CTLA-4 and PD-1 blockade in untreated metastatic melanoma. Science translational medicine. 2018 Academic Article GET IT
Times cited: 315
Lysis-independent potentiation of immune checkpoint blockade by oncolytic virus. Oncotarget. 2018 Academic Article GET IT
Times cited: 21
Adipocyte-Derived Lipids Mediate Melanoma Progression via FATP Proteins. Cancer discovery. 2018 Academic Article GET IT
Times cited: 189
Non-conventional Inhibitory CD4⁺Foxp3^-PD-1^hi T Cells as a Biomarker of Immune Checkpoint Blockade Activity. Cancer cell. 2018 Academic Article GET IT
Times cited: 96
STK11/LKB1 Mutations and PD-1 Inhibitor Resistance in KRAS-Mutant Lung Adenocarcinoma. Cancer discovery. 2018 Academic Article GET IT
Times cited: 860
Baseline Tumor Size Is an Independent Prognostic Factor for Overall Survival in Patients with Melanoma Treated with Pembrolizumab. Clinical cancer research : an official journal of the American Association for Cancer Research. 2018 Academic Article GET IT
Times cited: 197
Neoadjuvant PD-1 Blockade in Resectable Lung Cancer. The New England journal of medicine. 2018 Academic Article GET IT
Times cited: 1125
Cancer-Germline Antigen Expression Discriminates Clinical Outcome to CTLA-4 Blockade. Cell. 2018 Academic Article GET IT
Times cited: 88
Genomic Features of Response to Combination Immunotherapy in Patients with Advanced Non-Small-Cell Lung Cancer. Cancer cell. 2018 Academic Article GET IT
Times cited: 648
Emerging Concepts for Immune Checkpoint Blockade-Based Combination Therapies. Cancer cell. 2018 Review GET IT
Times cited: 326
Toxicological and pharmacological assessment of AGEN1884, a novel human IgG1 anti-CTLA-4 antibody. PloS one. 2018 Academic Article GET IT
Times cited: 16
Cancer immunotherapy using checkpoint blockade. Science (New York, N.Y.). 2018 Review GET IT
Times cited: 3285
PD-L1 in tumor microenvironment mediates resistance to oncolytic immunotherapy. The Journal of clinical investigation. 2018 Academic Article GET IT
Times cited: 87
Alterations in DNA Damage Response and Repair Genes as Potential Marker of Clinical Benefit From PD-1/PD-L1 Blockade in Advanced Urothelial Cancers. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2018 Academic Article GET IT
Times cited: 343
Introducing a New Series: Immunotherapy Facts and Hopes. Clinical cancer research : an official journal of the American Association for Cancer Research. 2018 Editorial Article GET IT
Times cited: 3
Peripheral blood clinical laboratory variables associated with outcomes following combination nivolumab and ipilimumab immunotherapy in melanoma. Cancer medicine. 2018 Academic Article GET IT
Times cited: 73
Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: American Society of Clinical Oncology Clinical Practice Guideline. 2018 GET IT
Times cited: 2162
Altered self: the not-so-neo-antigens. Nature reviews. Immunology. 2018 Comment GET IT
Times cited: 1
Pre-existing Immunity to Oncolytic Virus Potentiates Its Immunotherapeutic Efficacy. Molecular therapy : the journal of the American Society of Gene Therapy. 2018 Academic Article GET IT
Times cited: 88
Immune-Modified Response Evaluation Criteria In Solid Tumors (imRECIST): Refining Guidelines to Assess the Clinical Benefit of Cancer Immunotherapy. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2018 Academic Article GET IT
Times cited: 234
Activation of p53 in Immature Myeloid Precursor Cells Controls Differentiation into Ly6c⁺CD103⁺ Monocytic Antigen-Presenting Cells in Tumors. Immunity. 2018 Academic Article GET IT
Times cited: 77
Molecular Determinants of Response to Anti-Programmed Cell Death (PD)-1 and Anti-Programmed Death-Ligand 1 (PD-L1) Blockade in Patients With Non-Small-Cell Lung Cancer Profiled With Targeted Next-Generation Sequencing. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2018 Academic Article GET IT
Times cited: 882
Robust Antitumor Responses Result from Local Chemotherapy and CTLA-4 Blockade. Cancer immunology research. 2018 Academic Article GET IT
Times cited: 95
Introduction by the Guest Editors: The PD-1 Axis in Cancer Therapy: The Irony in a Name. Cancer journal (Sudbury, Mass.). 2018 Review GET IT
Measuring Toxic Effects and Time to Treatment Failure for Nivolumab Plus Ipilimumab in Melanoma. JAMA oncology. 2018 Academic Article GET IT
Times cited: 109
Durable Complete Response After Discontinuation of Pembrolizumab in Patients With Metastatic Melanoma. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2017 Academic Article GET IT
Times cited: 301
Nivolumab and Ipilimumab in Advanced Melanoma. The New England journal of medicine. 2017 Letter GET IT
Times cited: 14
Shared cancer neoantigens: Making private matters public. The Journal of experimental medicine. 2017 Comment GET IT
Times cited: 31
A neoantigen fitness model predicts tumour response to checkpoint blockade immunotherapy. Nature. 2017 Academic Article GET IT
Times cited: 395
Identification of unique neoantigen qualities in long-term survivors of pancreatic cancer. Nature. 2017 Academic Article GET IT
Times cited: 679
Nivolumab for Patients With Advanced Melanoma Treated Beyond Progression: Analysis of 2 Phase 3 Clinical Trials. JAMA oncology. 2017 Academic Article GET IT
Times cited: 122
Future cancer research priorities in the USA: a Lancet Oncology Commission. The Lancet. Oncology. 2017 Review GET IT
Times cited: 129
Melanoma brain metastases treated with stereotactic radiosurgery and concurrent pembrolizumab display marked regression; efficacy and safety of combined treatment. Journal for immunotherapy of cancer. 2017 Academic Article GET IT
Times cited: 84
Nivolumab Plus Ipilimumab in Patients With Advanced Melanoma: Updated Survival, Response, and Safety Data in a Phase I Dose-Escalation Study. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2017 Academic Article GET IT
Times cited: 132
Langerhans-type dendritic cells electroporated with TRP-2 mRNA stimulate cellular immunity against melanoma: Results of a phase I vaccine trial. Oncoimmunology. 2017 Academic Article GET IT
Times cited: 16
Four-month course of adjuvant dabrafenib in patients with surgically resected stage IIIC melanoma characterized by a BRAFV600E/K mutation. Oncotarget. 2017 Academic Article GET IT
Times cited: 7
Pooled Analysis Safety Profile of Nivolumab and Ipilimumab Combination Therapy in Patients With Advanced Melanoma. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2017 Academic Article GET IT
Times cited: 192
Overall Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma. The New England journal of medicine. 2017 Academic Article GET IT
Times cited: 2369
Blockade of surface-bound TGF-β on regulatory T cells abrogates suppression of effector T cell function in the tumor microenvironment. Science signaling. 2017 Academic Article GET IT
Times cited: 84
Efficacy and Safety Outcomes in Patients With Advanced Melanoma Who Discontinued Treatment With Nivolumab and Ipilimumab Because of Adverse Events: A Pooled Analysis of Randomized Phase II and III Trials. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2017 Academic Article GET IT
Times cited: 298
Heterogeneous Tumor-Immune Microenvironments among Differentially Growing Metastases in an Ovarian Cancer Patient. 2017 GET IT
Times cited: 317
Health-related quality of life results from the phase III CheckMate 067 study. European journal of cancer (Oxford, England : 1990). 2017 Academic Article GET IT
Times cited: 65
Curbing Tregs' (Lack of) Enthusiasm. Cell. 2017 Comment GET IT
Times cited: 4
Pilot study of safety and feasibility of DNA microseeding for treatment of spontaneous canine melanoma. Veterinary medicine and science. 2017 Academic Article GET IT
Times cited: 5
Intratumoral delivery of inactivated modified vaccinia virus Ankara (iMVA) induces systemic antitumor immunity via STING and Batf3-dependent dendritic cells. Science immunology. 2017 Academic Article GET IT
Times cited: 79
Chromatin states define tumour-specific T cell dysfunction and reprogramming. Nature. 2017 Academic Article GET IT
Times cited: 496
Checkpoint inhibition and melanoma: Considerations in treating the older adult. Journal of geriatric oncology. 2017 Review GET IT
Times cited: 23
T-cell invigoration to tumour burden ratio associated with anti-PD-1 response. Nature. 2017 Academic Article GET IT
Times cited: 1023
Inhibiting DNA Methylation Causes an Interferon Response in Cancer via dsRNA Including Endogenous Retroviruses. Cell. 2017 Academic Article GET IT
Times cited: 54
Neutrophil to Lymphocyte Ratio is Associated With Outcome During Ipilimumab Treatment. EBioMedicine. 2017 Academic Article GET IT
Times cited: 74
iRECIST: guidelines for response criteria for use in trials testing immunotherapeutics. The Lancet. Oncology. 2017 Review GET IT
Times cited: 1295
Antibody-mediated thyroid dysfunction during T-cell checkpoint blockade in patients with non-small-cell lung cancer. Annals of oncology : official journal of the European Society for Medical Oncology. 2017 Academic Article GET IT
Times cited: 419
Patient perspectives on ipilimumab across the melanoma treatment trajectory. Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer. 2017 Academic Article GET IT
Times cited: 12
Combination immunotherapy: a road map. Journal for immunotherapy of cancer. 2017 Review GET IT
Times cited: 265
Intratumoral modulation of the inducible co-stimulator ICOS by recombinant oncolytic virus promotes systemic anti-tumour immunity. Nature communications. 2017 Academic Article GET IT
Times cited: 93
Peripheral CD8 effector-memory type 1 T-cells correlate with outcome in ipilimumab-treated stage IV melanoma patients. European journal of cancer (Oxford, England : 1990). 2017 Academic Article GET IT
Times cited: 67
Health-related quality of life with adjuvant ipilimumab versus placebo after complete resection of high-risk stage III melanoma (EORTC 18071): secondary outcomes of a multinational, randomised, double-blind, phase 3 trial. The Lancet. Oncology. 2017 Academic Article GET IT
Times cited: 75
Clinical features and response to systemic therapy in a historical cohort of advanced or unresectable mucosal melanoma. Melanoma research. 2017 Academic Article GET IT
Times cited: 33
Cancer immunotherapy - immune checkpoint blockade and associated endocrinopathies. Nature reviews. Endocrinology. 2017 Review GET IT
Times cited: 434
An MHC-restricted antibody-based chimeric antigen receptor requires TCR-like affinity to maintain antigen specificity. Molecular therapy oncolytics. 2017 Academic Article GET IT
Times cited: 59
Validation of Anti-Mouse PDL-1 Goat Polyclonal Antibody Staining with Mouse PDL-1 In Situ Hybridization on Adjacent Sections of Cell Pellets and Mouse Tumors. Methods in molecular biology (Clifton, N.J.). 2017 Academic Article GET IT
Times cited: 1
Thinking Critically About Classifying Adverse Events: Incidence of Pancreatitis in Patients Treated With Nivolumab + Ipilimumab. Journal of the National Cancer Institute. 2016 Academic Article GET IT
Times cited: 49
Morphological characterization of colorectal cancers in The Cancer Genome Atlas reveals distinct morphology-molecular associations: clinical and biological implications. Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc. 2016 Academic Article GET IT
Times cited: 58
Somatic Mutations and Neoepitope Homology in Melanomas Treated with CTLA-4 Blockade. Cancer immunology research. 2016 Academic Article GET IT
Times cited: 90
Corrigendum: Melanoma exosomes educate bone marrow progenitor cells toward a pro-metastatic phenotype through MET. Nature medicine. 2016 Academic Article GET IT
Times cited: 29
Safety Profile of Nivolumab Monotherapy: A Pooled Analysis of Patients With Advanced Melanoma. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2016 Academic Article GET IT
Times cited: 791
Overcoming resistance to checkpoint blockade therapy by targeting PI3Kγ in myeloid cells. Nature. 2016 Academic Article GET IT
Times cited: 557
Efficacy and Safety of Nivolumab Alone or in Combination With Ipilimumab in Patients With Mucosal Melanoma: A Pooled Analysis. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2016 Academic Article GET IT
Times cited: 354
Successful Treatment of a Patient with Glioblastoma and a Germline POLE Mutation: Where Next?. Cancer discovery. 2016 Comment GET IT
Times cited: 13
T-Cell Therapy Using Interleukin-21-Primed Cytotoxic T-Cell Lymphocytes Combined With Cytotoxic T-Cell Lymphocyte Antigen-4 Blockade Results in Long-Term Cell Persistence and Durable Tumor Regression. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2016 Academic Article GET IT
Times cited: 77
Programmed Death-Ligand 1 Expression and Response to the Anti-Programmed Death 1 Antibody Pembrolizumab in Melanoma. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2016 Academic Article GET IT
Times cited: 448
An Open-Label, Dose-Escalation Phase I Study of Anti-TYRP1 Monoclonal Antibody IMC-20D7S for Patients with Relapsed or Refractory Melanoma. Clinical cancer research : an official journal of the American Association for Cancer Research. 2016 Academic Article GET IT
Times cited: 13
Prolonged Survival in Stage III Melanoma with Ipilimumab Adjuvant Therapy. The New England journal of medicine. 2016 Academic Article GET IT
Times cited: 1012
Pneumonitis in Patients Treated With Anti-Programmed Death-1/Programmed Death Ligand 1 Therapy. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2016 Academic Article GET IT
Times cited: 703
Kinase Regulation of Human MHC Class I Molecule Expression on Cancer Cells. Cancer immunology research. 2016 Academic Article GET IT
Times cited: 104
Combined nivolumab and ipilimumab versus ipilimumab alone in patients with advanced melanoma: 2-year overall survival outcomes in a multicentre, randomised, controlled, phase 2 trial. The Lancet. Oncology. 2016 Academic Article GET IT
Times cited: 686
Deep Sequencing of T-cell Receptor DNA as a Biomarker of Clonally Expanded TILs in Breast Cancer after Immunotherapy. Cancer immunology research. 2016 Academic Article GET IT
Times cited: 104
A Pilot Study of Preoperative Single-Dose Ipilimumab and/or Cryoablation in Women with Early-Stage Breast Cancer with Comprehensive Immune Profiling. Clinical cancer research : an official journal of the American Association for Cancer Research. 2016 Academic Article GET IT
Times cited: 128
The efficacy of anti-PD-1 agents in acral and mucosal melanoma. Cancer. 2016 Academic Article GET IT
Times cited: 205
Melanoma and immunotherapy bridge 2015 : Naples, Italy. 1-5 December 2015. Journal of translational medicine. 2016 Academic Article GET IT
Reply to M. Nishino. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2016 Letter GET IT
The metabolic/pH sensor soluble adenylyl cyclase is a tumor suppressor protein. Oncotarget. 2016 Academic Article GET IT
Times cited: 15
Proportions of blood-borne Vδ1+ and Vδ2+ T-cells are associated with overall survival of melanoma patients treated with ipilimumab. European journal of cancer (Oxford, England : 1990). 2016 Academic Article GET IT
Times cited: 46
Definite regression of cutaneous melanoma metastases upon addition of topical contact sensitizer diphencyprone to immune checkpoint inhibitor treatment. Experimental dermatology. 2016 Letter GET IT
Times cited: 14
In-depth tissue profiling using multiplexed immunohistochemical consecutive staining on single slide. Science immunology. 2016 Academic Article GET IT
Times cited: 101
Prognosis of Mucosal, Uveal, Acral, Nonacral Cutaneous, and Unknown Primary Melanoma From the Time of First Metastasis. The oncologist. 2016 Academic Article GET IT
Times cited: 128
Clinicopathological features of acute kidney injury associated with immune checkpoint inhibitors. Kidney international. 2016 Academic Article GET IT
Times cited: 387
A phase 2 trial of everolimus and pasireotide long-acting release in patients with metastatic uveal melanoma. Melanoma research. 2016 Academic Article GET IT
Times cited: 27
Combined IL-21-primed polyclonal CTL plus CTLA4 blockade controls refractory metastatic melanoma in a patient. The Journal of experimental medicine. 2016 Academic Article GET IT
Times cited: 62
RECIST 1.1 - Standardisation and disease-specific adaptations: Perspectives from the RECIST Working Group. European journal of cancer (Oxford, England : 1990). 2016 Review GET IT
Times cited: 169
Targeting T Cell Co-receptors for Cancer Therapy. Immunity. 2016 Review GET IT
Times cited: 358
Baseline Biomarkers for Outcome of Melanoma Patients Treated with Pembrolizumab. Clinical cancer research : an official journal of the American Association for Cancer Research. 2016 Academic Article GET IT
Times cited: 421
RECIST 1.1-Update and clarification: From the RECIST committee. European journal of cancer (Oxford, England : 1990). 2016 Academic Article GET IT
Times cited: 899
Increases in Absolute Lymphocytes and Circulating CD4+ and CD8+ T Cells Are Associated with Positive Clinical Outcome of Melanoma Patients Treated with Ipilimumab. Clinical cancer research : an official journal of the American Association for Cancer Research. 2016 Academic Article GET IT
Times cited: 123
Patient-Physician Communication in the 21st Century. Trends in immunology. 2016 Academic Article GET IT
Times cited: 1
The future of cancer treatment: immunomodulation, CARs and combination immunotherapy. Nature reviews. Clinical oncology. 2016 Academic Article GET IT
Times cited: 175
Timing of CSF-1/CSF-1R signaling blockade is critical to improving responses to CTLA-4 based immunotherapy. Oncoimmunology. 2016 Academic Article GET IT
Times cited: 4274
Association of Pembrolizumab With Tumor Response and Survival Among Patients With Advanced Melanoma. JAMA. 2016 Academic Article GET IT
Times cited: 772
Toxicities of the anti-PD-1 and anti-PD-L1 immune checkpoint antibodies. Annals of oncology : official journal of the European Society for Medical Oncology. 2016 Academic Article GET IT
Times cited: 112
Characterisation and management of dermatologic adverse events to agents targeting the PD-1 receptor. European journal of cancer (Oxford, England : 1990). 2016 Review GET IT
Times cited: 287
Immunodynamics: a cancer immunotherapy trials network review of immune monitoring in immuno-oncology clinical trials. Journal for immunotherapy of cancer. 2016 Review GET IT
Times cited: 422
The future of cancer treatment: immunomodulation, CARs and combination immunotherapy. Nature reviews. Clinical oncology. 2016 Review GET IT
Times cited: 702
Evaluation of Immune-Related Response Criteria and RECIST v1.1 in Patients With Advanced Melanoma Treated With Pembrolizumab. 2016 GET IT
Times cited: 547
Clonal neoantigens elicit T cell immunoreactivity and sensitivity to immune checkpoint blockade. Science (New York, N.Y.). 2016 Academic Article GET IT
Times cited: 2058
PD-L1 (B7-H1) and PD-1 pathway blockade for cancer therapy: Mechanisms, response biomarkers, and combinations. Science translational medicine. 2016 Review GET IT
Times cited: 1556
Autoimmune Bullous Skin Disorders with Immune Checkpoint Inhibitors Targeting PD-1 and PD-L1. 2016 GET IT
Times cited: 217
Inhibiting DNA Methylation Causes an Interferon Response in Cancer via dsRNA Including Endogenous Retroviruses. Cell. 2016 Article GET IT
Times cited: 49
Targeting myeloid-derived suppressor cells with colony stimulating factor-1 receptor blockade can reverse immune resistance to immunotherapy in indoleamine 2,3-dioxygenase-expressing tumors. EBioMedicine. 2016 Academic Article GET IT
Times cited: 106
Negative local resistance caused by viscous electron backflow in graphene. Science (New York, N.Y.). 2016 Academic Article GET IT
Chemokine receptor patterns in lymphocytes mirror metastatic spreading in melanoma. The Journal of clinical investigation. 2016 Academic Article GET IT
Times cited: 57
Intestinal microbiome analyses identify melanoma patients at risk for checkpoint-blockade-induced colitis. Nature communications. 2016 Academic Article GET IT
Times cited: 663
Baseline Peripheral Blood Biomarkers Associated with Clinical Outcome of Advanced Melanoma Patients Treated with Ipilimumab. Clinical cancer research : an official journal of the American Association for Cancer Research. 2016 Academic Article GET IT
Times cited: 415
Clonal Abundance of Tumor-Specific CD4(+) T Cells Potentiates Efficacy and Alters Susceptibility to Exhaustion. Immunity. 2016 Academic Article GET IT
Times cited: 28
Reply to A. Indini et al. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2016 Letter GET IT
Combinatorial Cancer Immunotherapies. Advances in immunology. 2016 Review GET IT
Times cited: 87
IMMUNOTHERAPY. Could microbial therapy boost cancer immunotherapy?. Science (New York, N.Y.). 2015 Comment GET IT
Times cited: 32
CCR 20th Anniversary Commentary: Immune-Related Response Criteria--Capturing Clinical Activity in Immuno-Oncology. Clinical cancer research : an official journal of the American Association for Cancer Research. 2015 Comment GET IT
Times cited: 43
Genetic Basis for Clinical Response to CTLA-4 Blockade in Melanoma. The New England journal of medicine. 2015 Letter GET IT
Times cited: 121
The PTEN pathway in Tregs is a critical driver of the suppressive tumor microenvironment. Science advances. 2015 Academic Article GET IT
Times cited: 129
Phase I Clinical Trial of Ipilimumab in Pediatric Patients with Advanced Solid Tumors. Clinical cancer research : an official journal of the American Association for Cancer Research. 2015 Academic Article GET IT
Times cited: 222
Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma. The New England journal of medicine. 2015 Letter GET IT
Times cited: 577
Tumor-Expressed IDO Recruits and Activates MDSCs in a Treg-Dependent Manner. Cell reports. 2015 Academic Article GET IT
Times cited: 324
Toxicities of the anti-PD-1 and anti-PD-L1 immune checkpoint antibodies. Annals of oncology : official journal of the European Society for Medical Oncology. 2015 Review GET IT
Times cited: 966
Immunotherapy of Melanoma. Progress in tumor research. 2015 Review GET IT
Times cited: 13
Inhibiting DNA Methylation Causes an Interferon Response in Cancer via dsRNA Including Endogenous Retroviruses. Cell. 2015 Academic Article GET IT
Times cited: 1043
PD-1 Blockers. Cell. 2015 Academic Article GET IT
Times cited: 111
Immune-Related Adverse Events, Need for Systemic Immunosuppression, and Effects on Survival and Time to Treatment Failure in Patients With Melanoma Treated With Ipilimumab at Memorial Sloan Kettering Cancer Center. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2015 Academic Article GET IT
Times cited: 749
Efficacy and Safety of Nivolumab in Patients With BRAF V600 Mutant and BRAF Wild-Type Advanced Melanoma: A Pooled Analysis of 4 Clinical Trials. JAMA oncology. 2015 Review GET IT
Times cited: 186
Safety of Infusing Ipilimumab Over 30 Minutes. 2015 GET IT
Times cited: 20
Pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory melanoma (KEYNOTE-002): a randomised, controlled, phase 2 trial. The Lancet. Oncology. 2015 Academic Article GET IT
Times cited: 1263
Peripheral T cell receptor diversity is associated with clinical outcomes following ipilimumab treatment in metastatic melanoma. Journal for immunotherapy of cancer. 2015 Academic Article GET IT
Times cited: 149
The New Era of Cancer Immunotherapy: Manipulating T-Cell Activity to Overcome Malignancy. Advances in cancer research. 2015 Review GET IT
Times cited: 40
Clinical Activity, Toxicity, Biomarkers, and Future Development of CTLA-4 Checkpoint Antagonists. Seminars in oncology. 2015 Review GET IT
Times cited: 18
Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma. The New England journal of medicine. 2015 Academic Article GET IT
Times cited: 5387
Genomic profile, smoking, and response to anti-PD-1 therapy in non-small cell lung carcinoma. Molecular & cellular oncology. 2015 Academic Article GET IT
Times cited: 3127
Clinical Activity of Ipilimumab in Acral Melanoma: A Retrospective Review. The oncologist. 2015 Academic Article GET IT
Times cited: 31
Id1 suppresses anti-tumour immune responses and promotes tumour progression by impairing myeloid cell maturation. Nature communications. 2015 Academic Article GET IT
Times cited: 72
Nivolumab and ipilimumab versus ipilimumab in untreated melanoma. The New England journal of medicine. 2015 Academic Article GET IT
Times cited: 2177
Rapid eradication of a bulky melanoma mass with one dose of immunotherapy. The New England journal of medicine. 2015 Letter GET IT
Times cited: 53
Genetics and immunology: reinvigorated. Oncoimmunology. 2015 Academic Article GET IT
Times cited: 3186
Immunotherapy: The path to win the war on cancer?. Cell. 2015 Academic Article GET IT
Times cited: 79
Adjuvant ipilimumab versus placebo after complete resection of high-risk stage III melanoma (EORTC 18071): a randomised, double-blind, phase 3 trial. The Lancet. Oncology. 2015 Academic Article GET IT
Times cited: 948
On being less tolerant: enhanced cancer immunosurveillance enabled by targeting checkpoints and agonists of T cell activation. Science translational medicine. 2015 Review GET IT
Times cited: 123
Cancer immunology. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer. Science (New York, N.Y.). 2015 Academic Article GET IT
Times cited: 5785
Stereotactic radiosurgery for melanoma brain metastases in patients receiving ipilimumab: safety profile and efficacy of combined treatment. International journal of radiation oncology, biology, physics. 2015 Academic Article GET IT
Times cited: 291
Erratum: anticancer immunotherapy by CTLA-4 blockade: obligatory contribution of IL-2 receptors and negative prognostic impact of soluble CD25. Cell research. 2015 Article GET IT
Times cited: 19
Five-year survival rates for treatment-naive patients with advanced melanoma who received ipilimumab plus dacarbazine in a phase III trial. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2015 Academic Article GET IT
Times cited: 374
Genetic basis for clinical response to CTLA-4 blockade. The New England journal of medicine. 2015 Letter GET IT
Times cited: 53
Phase II Study of Nilotinib in Melanoma Harboring KIT Alterations Following Progression to Prior KIT Inhibition. Clinical cancer research : an official journal of the American Association for Cancer Research. 2015 Academic Article GET IT
Times cited: 96
Pooled Analysis of Long-Term Survival Data From Phase II and Phase III Trials of Ipilimumab in Unresectable or Metastatic Melanoma. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2015 Review GET IT
Times cited: 1572
Immune-priming of the tumor microenvironment by radiotherapy: rationale for combination with immunotherapy to improve anticancer efficacy. American journal of clinical oncology. 2015 Review GET IT
Times cited: 74
Immune Checkpoint Blockade in Cancer Therapy. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2015 Review GET IT
Times cited: 1928
Requirement for innate immunity and CD90⁺ NK1.1⁻ lymphocytes to treat established melanoma with chemo-immunotherapy. Cancer immunology research. 2015 Academic Article GET IT
Times cited: 20
CTLA-4 and PD-1 Pathway Blockade: Combinations in the Clinic. Frontiers in oncology. 2015 Review GET IT
Times cited: 2383
Anticancer immunotherapy by CTLA-4 blockade: obligatory contribution of IL-2 receptors and negative prognostic impact of soluble CD25. Cell research. 2015 Academic Article GET IT
Times cited: 118
Classification of current anticancer immunotherapies. Oncotarget. 2014 Review GET IT
Times cited: 340
Expanded access programmes: patient interests versus clinical trial integrity. The Lancet. Oncology. 2014 Academic Article GET IT
Times cited: 8
Combination therapy with anti-CTLA-4 and anti-PD-1 leads to distinct immunologic changes in vivo. Journal of immunology (Baltimore, Md. : 1950). 2014 Academic Article GET IT
Times cited: 313
Potentiation of immunomodulatory antibody therapy with oncolytic viruses for treatment of cancer. Molecular therapy oncolytics. 2014 Review GET IT
Times cited: 31
Cancer: Antitumour immunity gets a boost. Nature. 2014 Academic Article GET IT
Times cited: 81
Open access is tiring out peer reviewers. Nature. 2014 Academic Article GET IT
Times cited: 33
Genetic basis for clinical response to CTLA-4 blockade in melanoma. The New England journal of medicine. 2014 Academic Article GET IT
Times cited: 3140
Immunotherapy and the belly of the beast. The Journal of experimental medicine. 2014 Comment GET IT
Times cited: 1
CTLA-4 antibodies: new directions, new combinations. Oncology (Williston Park, N.Y.). 2014 Review GET IT
Times cited: 23
Ipilimumab in patients with melanoma and autoimmune disease. Journal for immunotherapy of cancer. 2014 Academic Article GET IT
Times cited: 87
Ipilimumab and whole brain radiation therapy for melanoma brain metastases. Journal of neuro-oncology. 2014 Academic Article GET IT
Times cited: 45
Immune modulation for cancer therapy. British journal of cancer. 2014 Review GET IT
Times cited: 118
Survival follow-up and ipilimumab retreatment of patients with advanced melanoma who received ipilimumab in prior phase II studies. Annals of oncology : official journal of the European Society for Medical Oncology. 2014 Academic Article GET IT
Times cited: 123
Anti-programmed-death-receptor-1 treatment with pembrolizumab in ipilimumab-refractory advanced melanoma: a randomised dose-comparison cohort of a phase 1 trial. Lancet (London, England). 2014 Academic Article GET IT
Times cited: 1482
Durable benefit and the potential for long-term survival with immunotherapy in advanced melanoma. Cancer treatment reviews. 2014 Review GET IT
Times cited: 157
Effect of selumetinib vs chemotherapy on progression-free survival in uveal melanoma: a randomized clinical trial. JAMA. 2014 Academic Article GET IT
Times cited: 324
Opportunistic infections in patients treated with immunotherapy for cancer. Journal for immunotherapy of cancer. 2014 Academic Article GET IT
Times cited: 1263
A phase 2 randomised study of ramucirumab (IMC-1121B) with or without dacarbazine in patients with metastatic melanoma. European journal of cancer (Oxford, England : 1990). 2014 Academic Article GET IT
Times cited: 19
Immune checkpoint blockade. Hematology/oncology clinics of North America. 2014 Review GET IT
Times cited: 65
Computational algorithm-driven evaluation of monocytic myeloid-derived suppressor cell frequency for prediction of clinical outcomes. Cancer immunology research. 2014 Academic Article GET IT
Times cited: 104
Cancer's off switch. Scientific American. 2014 Academic Article GET IT
Times cited: 1
Ipilimumab in patients with cancer and the management of dermatologic adverse events. Journal of the American Academy of Dermatology. 2014 Review GET IT
Times cited: 141
Targeting tumor-necrosis factor receptor pathways for tumor immunotherapy. Journal for immunotherapy of cancer. 2014 Review GET IT
Times cited: 1694
T cells translate individual, quantal activation into collective, analog cytokine responses via time-integrated feedbacks. eLife. 2014 Academic Article GET IT
Times cited: 49
Pituitary expression of CTLA-4 mediates hypophysitis secondary to administration of CTLA-4 blocking antibody. Science translational medicine. 2014 Academic Article GET IT
Times cited: 465
Endocrine-related adverse events following ipilimumab in patients with advanced melanoma: a comprehensive retrospective review from a single institution. Endocrine-related cancer. 2014 Review GET IT
Times cited: 318
Localized oncolytic virotherapy overcomes systemic tumor resistance to immune checkpoint blockade immunotherapy. Science translational medicine. 2014 Academic Article GET IT
Times cited: 535
Combination of alphavirus replicon particle-based vaccination with immunomodulatory antibodies: therapeutic activity in the B16 melanoma mouse model and immune correlates. Cancer immunology research. 2014 Academic Article GET IT
Times cited: 30
Anaphylaxis caused by repetitive doses of a GITR agonist monoclonal antibody in mice. Blood. 2014 Academic Article GET IT
Times cited: 22
Dissection of immune gene networks in primary melanoma tumors critical for antitumor surveillance of patients with stage II-III resectable disease. The Journal of investigative dermatology. 2014 Academic Article GET IT
Times cited: 45
Pretreatment serum VEGF is associated with clinical response and overall survival in advanced melanoma patients treated with ipilimumab. Cancer immunology research. 2014 Academic Article GET IT
Times cited: 111
Cutis verticis gyrata in association with vemurafenib and whole-brain radiotherapy. 2014 GET IT
Times cited: 34
Markers for anti-cytotoxic T-lymphocyte antigen 4 (CTLA-4) therapy in melanoma. Methods in molecular biology (Clifton, N.J.). 2014 Academic Article GET IT
Times cited: 7
Paradoxical activation of T cells via augmented ERK signaling mediated by a RAF inhibitor. Cancer immunology research. 2014 Academic Article GET IT
Times cited: 87
The importance of animal models in tumor immunity and immunotherapy. Current opinion in genetics & development. 2013 Review GET IT
Times cited: 56
Enhanced responses to tumor immunization following total body irradiation are time-dependent. PloS one. 2013 Academic Article GET IT
Times cited: 11
Immunologic responses to xenogeneic tyrosinase DNA vaccine administered by electroporation in patients with malignant melanoma. Journal for immunotherapy of cancer. 2013 Academic Article GET IT
Times cited: 11
GITR pathway activation abrogates tumor immune suppression through loss of regulatory T cell lineage stability. Cancer immunology research. 2013 Academic Article GET IT
Times cited: 119
Immune modulation in cancer with antibodies. Annual review of medicine. 2013 Review GET IT
Times cited: 397
Depression, cytokines, and pancreatic cancer. Psycho-oncology. 2013 Academic Article GET IT
Times cited: 68
Checkpoint modulation in melanoma: an update on ipilimumab and future directions. Current oncology reports. 2013 Review GET IT
Times cited: 17
Enhancement of tumor-reactive cytotoxic CD4+ T cell responses after ipilimumab treatment in four advanced melanoma patients. 2013 GET IT
Times cited: 89
Irreversible electroporation facilitates gene transfer of a GM-CSF plasmid with a local and systemic response. Surgery. 2013 Academic Article GET IT
Times cited: 17
The delicate balance of melanoma immunotherapy. Clinical & translational immunology. 2013 Review GET IT
Times cited: 623
Clinical activity of ipilimumab for metastatic uveal melanoma: a retrospective review of the Dana-Farber Cancer Institute, Massachusetts General Hospital, Memorial Sloan-Kettering Cancer Center, and University Hospital of Lausanne experience. Cancer. 2013 Academic Article GET IT
Times cited: 150
Increased frequency of ICOS+ CD4 T cells as a pharmacodynamic biomarker for anti-CTLA-4 therapy. Cancer immunology research. 2013 Academic Article GET IT
Times cited: 151
Fc-dependent depletion of tumor-infiltrating regulatory T cells co-defines the efficacy of anti-CTLA-4 therapy against melanoma. The Journal of experimental medicine. 2013 Academic Article GET IT
Times cited: 1031
Concurrent radiotherapy and ipilimumab immunotherapy for patients with melanoma. Cancer immunology research. 2013 Review GET IT
Times cited: 123
Two Distinct Categories of Focal Deletions in Cancer Genomes. PloS one. 2013 Academic Article GET IT
Times cited: 29
Development of ipilimumab: a novel immunotherapeutic approach for the treatment of advanced melanoma. Annals of the New York Academy of Sciences. 2013 Review GET IT
Times cited: 440
Indoleamine 2,3-dioxygenase is a critical resistance mechanism in antitumor T cell immunotherapy targeting CTLA-4. The Journal of experimental medicine. 2013 Academic Article GET IT
Times cited: 492
Nivolumab plus ipilimumab in advanced melanoma. The New England journal of medicine. 2013 Academic Article GET IT
Times cited: 3352
Safety and tumor responses with lambrolizumab (anti-PD-1) in melanoma. The New England journal of medicine. 2013 Academic Article GET IT
Times cited: 2756
Ipilimumab for patients with advanced mucosal melanoma. The oncologist. 2013 Academic Article GET IT
Times cited: 125
Immunological insights from patients undergoing surgery on ipilimumab for metastatic melanoma. Annals of surgical oncology. 2013 Academic Article GET IT
Times cited: 40
At the bedside: CTLA-4- and PD-1-blocking antibodies in cancer immunotherapy. Journal of leukocyte biology. 2013 Review GET IT
Times cited: 271
Four-year survival rates for patients with metastatic melanoma who received ipilimumab in phase II clinical trials. Annals of oncology : official journal of the European Society for Medical Oncology. 2013 Academic Article GET IT
Times cited: 146
Randomized phase I pharmacokinetic study of ipilimumab with or without one of two different chemotherapy regimens in patients with untreated advanced melanoma. Cancer immunity. 2013 Academic Article GET IT
Times cited: 70
Hepatotoxicity with combination of vemurafenib and ipilimumab. The New England journal of medicine. 2013 Letter GET IT
Times cited: 593
Combining cancer immunotherapy and targeted therapy. Current opinion in immunology. 2013 Review GET IT
Times cited: 52
Agonist antibodies to TNFR molecules that costimulate T and NK cells. Clinical cancer research : an official journal of the American Association for Cancer Research. 2013 Academic Article GET IT
Times cited: 127
Biomarkers for immunostimulatory monoclonal antibodies in combination strategies for melanoma and other tumor types. Clinical cancer research : an official journal of the American Association for Cancer Research. 2013 Academic Article GET IT
Times cited: 121
Phase II trial of MEK inhibitor selumetinib (AZD6244, ARRY-142886) in patients with BRAFV600E/K-mutated melanoma. Clinical cancer research : an official journal of the American Association for Cancer Research. 2013 Academic Article GET IT
Times cited: 111
Myeloid-derived suppressor sells and the efficacy of CD8⁺ T-cell immunotherapy. Oncoimmunology. 2013 Academic Article GET IT
Times cited: 1584
Immunomodulatory therapy for melanoma: ipilimumab and beyond. Clinics in dermatology. 2013 Review GET IT
Times cited: 53
Patient responses to ipilimumab, a novel immunopotentiator for metastatic melanoma: how different are these from conventional treatment responses?. American journal of clinical oncology. 2012 Review GET IT
Times cited: 59
Relief of profound feedback inhibition of mitogenic signaling by RAF inhibitors attenuates their activity in BRAFV600E melanomas. Cancer cell. 2012 Academic Article GET IT
Times cited: 397
Progression of RAS-mutant leukemia during RAF inhibitor treatment. 2012 GET IT
Times cited: 197
Emerging therapies in melanoma. Clinical advances in hematology & oncology : H&O. 2012 Academic Article GET IT
Times cited: 2
Recombinant human interleukin-7 (CYT107) promotes T-cell recovery after allogeneic stem cell transplantation. Blood. 2012 Academic Article GET IT
Times cited: 135
Induction of tumoricidal function in CD4+ T cells is associated with concomitant memory and terminally differentiated phenotype. The Journal of experimental medicine. 2012 Academic Article GET IT
Times cited: 110
How recent advances in immunotherapy are changing the standard of care for patients with metastatic melanoma. Annals of oncology : official journal of the European Society for Medical Oncology. 2012 Review GET IT
Times cited: 56
Phase I/II study of pegylated arginine deiminase (ADI-PEG 20) in patients with advanced melanoma. Investigational new drugs. 2012 Academic Article GET IT
Times cited: 112
Melanoma exosomes educate bone marrow progenitor cells toward a pro-metastatic phenotype through MET. Nature medicine. 2012 Academic Article GET IT
Times cited: 2722
The abscopal effect associated with a systemic anti-melanoma immune response. 2012 GET IT
Times cited: 309
Monoclonal antibodies in cancer therapy. Cancer immunity. 2012 Review GET IT
Times cited: 319
Selecting antigens for cancer vaccines. Nature biotechnology. 2012 Comment GET IT
Times cited: 6
Alan Houghton. Pigment cell & melanoma research. 2012 Academic Article GET IT
Ipilimumab in patients with melanoma and brain metastases: an open-label, phase 2 trial. The Lancet. Oncology. 2012 Academic Article GET IT
Times cited: 865
Antibody therapy of cancer. Nature reviews. Cancer. 2012 Review GET IT
Times cited: 1623
Immunologic correlates of the abscopal effect in a patient with melanoma. 2012 GET IT
Times cited: 1584
The antitumor immunity of ipilimumab: (T-cell) memories to last a lifetime?. Clinical cancer research : an official journal of the American Association for Cancer Research. 2012 Comment GET IT
Times cited: 26
Modulation of GITR for cancer immunotherapy. Current opinion in immunology. 2012 Review GET IT
Times cited: 114
Targeting immune checkpoints: releasing the restraints on anti-tumor immunity for patients with melanoma. Cancer journal (Sudbury, Mass.). 2012 Review GET IT
Times cited: 55
Monocytic CCR2(+) myeloid-derived suppressor cells promote immune escape by limiting activated CD8 T-cell infiltration into the tumor microenvironment. Cancer research. 2011 Academic Article GET IT
Times cited: 270
Defining the critical hurdles in cancer immunotherapy. Journal of translational medicine. 2011 Editorial Article GET IT
Times cited: 138
Characterization of computed tomography scan abnormalities in patients with biopsy-proven hepatic metastases from uveal melanoma. Archives of ophthalmology (Chicago, Ill. : 1960). 2011 Academic Article GET IT
Times cited: 14
Safety and efficacy of a xenogeneic DNA vaccine encoding for human tyrosinase as adjunctive treatment for oral malignant melanoma in dogs following surgical excision of the primary tumor. American journal of veterinary research. 2011 Academic Article GET IT
Times cited: 157
Novel cancer immunotherapy agents with survival benefit: recent successes and next steps. Nature reviews. Cancer. 2011 Review GET IT
Times cited: 514
Treatment of locally recurrent mucosal melanoma with topical imiquimod. 2011 GET IT
Times cited: 30
Hiding the road signs that lead to tumor immunity. The Journal of experimental medicine. 2011 Review GET IT
Times cited: 12
Integrated NY-ESO-1 antibody and CD8+ T-cell responses correlate with clinical benefit in advanced melanoma patients treated with ipilimumab. Proceedings of the National Academy of Sciences of the United States of America. 2011 Academic Article GET IT
Times cited: 278
Altered development of NKT cells, γδ T cells, CD8 T cells and NK cells in a PLZF deficient patient. PloS one. 2011 Academic Article GET IT
Times cited: 49
Imatinib potentiates antitumor T cell responses in gastrointestinal stromal tumor through the inhibition of Ido. Nature medicine. 2011 Academic Article GET IT
Times cited: 431
Concurrent loss of the PTEN and RB1 tumor suppressors attenuates RAF dependence in melanomas harboring (V600E)BRAF. Oncogene. 2011 Academic Article GET IT
Times cited: 159
Detection of intra-tumor self antigen recognition during melanoma tumor progression in mice using advanced multimode confocal/two photon microscope. PloS one. 2011 Academic Article GET IT
Times cited: 12
Multimodal silica nanoparticles are effective cancer-targeted probes in a model of human melanoma. The Journal of clinical investigation. 2011 Academic Article GET IT
Times cited: 544
KIT as a therapeutic target in metastatic melanoma. JAMA. 2011 Academic Article GET IT
Times cited: 659
Ipilimumab plus dacarbazine for previously untreated metastatic melanoma. The New England journal of medicine. 2011 Academic Article GET IT
Times cited: 3631
CTLA-4 blockade increases antigen-specific CD8(+) T cells in prevaccinated patients with melanoma: three cases. Cancer immunology, immunotherapy : CII. 2011 Review GET IT
Times cited: 75
Therapeutic implications of the emerging molecular biology of uveal melanoma. Clinical cancer research : an official journal of the American Association for Cancer Research. 2011 Academic Article GET IT
Times cited: 93
Combination of epitope-optimized DNA vaccination and passive infusion of monoclonal antibody against HER2/neu leads to breast tumor regression in mice. Vaccine. 2011 Academic Article GET IT
Times cited: 11
Peptide-loaded Langerhans cells, despite increased IL15 secretion and T-cell activation in vitro, elicit antitumor T-cell responses comparable to peptide-loaded monocyte-derived dendritic cells in vivo. Clinical cancer research : an official journal of the American Association for Cancer Research. 2011 Academic Article GET IT
Times cited: 63
Beyond cancer vaccines: a reason for future optimism with immunomodulatory therapy. Cancer journal (Sudbury, Mass.). 2011 Review GET IT
Times cited: 24
Modulation of CTLA-4 and GITR for cancer immunotherapy. Current topics in microbiology and immunology. 2011 Review GET IT
Times cited: 26
Xenogeneic murine tyrosinase DNA vaccine for malignant melanoma of the digit of dogs. Journal of veterinary internal medicine. 2010 Academic Article GET IT
Times cited: 51
Anti-GITR antibodies--potential clinical applications for tumor immunotherapy. Current opinion in investigational drugs (London, England : 2000). 2010 Review GET IT
Times cited: 34
Improving the therapeutic benefits of ipilimumab. Oncology (Williston Park, N.Y.). 2010 Comment GET IT
Keratoacanthomas associated with imatinib mesylate. Acta oncologica (Stockholm, Sweden). 2010 Letter GET IT
Times cited: 5
Ipilimumab efficacy and safety in patients with advanced melanoma: a retrospective analysis of HLA subtype from four trials. Cancer immunity. 2010 Academic Article GET IT
Times cited: 121
Anti-CTLA-4 antibody therapy: immune monitoring during clinical development of a novel immunotherapy. Seminars in oncology. 2010 Review GET IT
Times cited: 196
Frequent MAGE mutations in human melanoma. PloS one. 2010 Academic Article GET IT
Times cited: 27
Alphavirus replicon particles expressing TRP-2 provide potent therapeutic effect on melanoma through activation of humoral and cellular immunity. PloS one. 2010 Academic Article GET IT
Times cited: 58
Improved endpoints for cancer immunotherapy trials. Journal of the National Cancer Institute. 2010 Review GET IT
Times cited: 464
Immunologic response to xenogeneic gp100 DNA in melanoma patients: comparison of particle-mediated epidermal delivery with intramuscular injection. Clinical cancer research : an official journal of the American Association for Cancer Research. 2010 Academic Article GET IT
Times cited: 43
WT1 peptide vaccinations induce CD4 and CD8 T cell immune responses in patients with mesothelioma and non-small cell lung cancer. Cancer immunology, immunotherapy : CII. 2010 Academic Article GET IT
Times cited: 102
Improved survival with ipilimumab in patients with metastatic melanoma. The New England journal of medicine. 2010 Academic Article GET IT
Times cited: 11579
Radiotherapy after surgical resection for head and neck mucosal melanoma. American journal of clinical oncology. 2010 Academic Article GET IT
Times cited: 54
Preoperative CTLA-4 blockade: tolerability and immune monitoring in the setting of a presurgical clinical trial. Clinical cancer research : an official journal of the American Association for Cancer Research. 2010 Academic Article GET IT
Times cited: 366
Agonist anti-GITR monoclonal antibody induces melanoma tumor immunity in mice by altering regulatory T cell stability and intra-tumor accumulation. PloS one. 2010 Academic Article GET IT
Times cited: 211
Targeting cytotoxic T-lymphocyte antigen 4 in immunotherapies for melanoma and other cancers. Immunotherapy. 2010 Review GET IT
Times cited: 20
Vaccination with synthetic analog peptides derived from WT1 oncoprotein induces T-cell responses in patients with complete remission from acute myeloid leukemia. Blood. 2010 Academic Article GET IT
Times cited: 131
Single-institution experience with ipilimumab in advanced melanoma patients in the compassionate use setting: lymphocyte count after 2 doses correlates with survival. Cancer. 2010 Academic Article GET IT
Times cited: 373
Cyclophosphamide enhances immunity by modulating the balance of dendritic cell subsets in lymphoid organs. Blood. 2010 Academic Article GET IT
Times cited: 96
Efficacy and safety of ipilimumab monotherapy in patients with pretreated advanced melanoma: a multicenter single-arm phase II study. Annals of oncology : official journal of the European Society for Medical Oncology. 2010 Academic Article GET IT
Times cited: 447
Phase II trial of neoadjuvant temozolomide in resectable melanoma patients. Annals of oncology : official journal of the European Society for Medical Oncology. 2010 Academic Article GET IT
Times cited: 24
Correlation of clinical and immunological data in a metastatic melanoma patient with heterogeneous tumor responses to ipilimumab therapy. 2010 GET IT
Times cited: 26
Immune regulatory antibodies: are they the next advance?. Cancer journal (Sudbury, Mass.). 2010 Review GET IT
Times cited: 25
Ipilimumab monotherapy in patients with pretreated advanced melanoma: a randomised, double-blind, multicentre, phase 2, dose-ranging study. The Lancet. Oncology. 2009 Academic Article GET IT
Times cited: 965
Guidelines for the evaluation of immune therapy activity in solid tumors: immune-related response criteria. Clinical cancer research : an official journal of the American Association for Cancer Research. 2009 Academic Article GET IT
Times cited: 2591
Completely regressed cutaneous melanocytic lesion: was it benign or was it malignant? 2009 GET IT
Times cited: 3
Cutting Edge: OX40 agonists can drive regulatory T cell expansion if the cytokine milieu is right. Journal of immunology (Baltimore, Md. : 1950). 2009 Academic Article GET IT
Times cited: 125
Safety and immunogenicity of a human and mouse gp100 DNA vaccine in a phase I trial of patients with melanoma. Cancer immunity. 2009 Academic Article GET IT
Times cited: 79
OX40 engagement and chemotherapy combination provides potent antitumor immunity with concomitant regulatory T cell apoptosis. The Journal of experimental medicine. 2009 Academic Article GET IT
Times cited: 177
Immune rejection of mouse tumors expressing mutated self. Cancer research. 2009 Academic Article GET IT
Times cited: 14
Self-antigen-specific CD8+ T cell precursor frequency determines the quality of the antitumor immune response. The Journal of experimental medicine. 2009 Academic Article GET IT
Times cited: 87
Direct economic burden of high-risk and metastatic melanoma in the elderly: evidence from the SEER-Medicare linked database. Applied health economics and health policy. 2009 Academic Article GET IT
Times cited: 17
Optimization and validation of a robust human T-cell culture method for monitoring phenotypic and polyfunctional antigen-specific CD4 and CD8 T-cell responses. Cytotherapy. 2009 Academic Article GET IT
Times cited: 33
Development of effective vaccines for old mice in a tumor model. Vaccine. 2008 Academic Article GET IT
Times cited: 6
Phase II trial of 17-allylamino-17-demethoxygeldanamycin in patients with metastatic melanoma. Clinical cancer research : an official journal of the American Association for Cancer Research. 2008 Academic Article GET IT
Times cited: 172
CTLA-4 blockade enhances polyfunctional NY-ESO-1 specific T cell responses in metastatic melanoma patients with clinical benefit. Proceedings of the National Academy of Sciences of the United States of America. 2008 Academic Article GET IT
Times cited: 293
Improved tumor immunity using anti-tyrosinase related protein-1 monoclonal antibody combined with DNA vaccines in murine melanoma. Cancer research. 2008 Academic Article GET IT
Times cited: 27
Keratinocyte growth factor enhances DNA plasmid tumor vaccine responses after murine allogeneic bone marrow transplantation. Blood. 2008 Academic Article GET IT
Times cited: 24
Phase I/II study of GM-CSF DNA as an adjuvant for a multipeptide cancer vaccine in patients with advanced melanoma. Molecular therapy : the journal of the American Society of Gene Therapy. 2008 Academic Article GET IT
Times cited: 75
Phase II study of extended-dose temozolomide in patients with melanoma. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2008 Academic Article GET IT
Times cited: 58
Rapid enlargement of a malignant melanoma in a child with vitiligo vulgaris after application of topical tacrolimus. Archives of dermatology. 2008 Letter GET IT
Times cited: 9
Mechanisms of immunization against cancer using chimeric antigens. Molecular therapy : the journal of the American Society of Gene Therapy. 2008 Academic Article GET IT
Times cited: 13
Meeting report: fourth international congress of the Society for Melanoma Research. Pigment cell & melanoma research. 2008 Conference Paper GET IT
Times cited: 6
The heterogeneity of the kinetics of response to ipilimumab in metastatic melanoma: patient cases. 2008 GET IT
Times cited: 122
The mechanism of anti-CTLA-4 activity and the negative regulation of T-cell activation. The oncologist. 2008 Review GET IT
Times cited: 190
Antibody and CD8+ T cell responses against HER2/neu required for tumor eradication after DNA immunization with a Flt-3 ligand fusion vaccine. Clinical cancer research : an official journal of the American Association for Cancer Research. 2007 Academic Article GET IT
Times cited: 24
Safety and immunogenicity of tyrosinase DNA vaccines in patients with melanoma. Molecular therapy : the journal of the American Society of Gene Therapy. 2007 Academic Article GET IT
Times cited: 86
Stage-IV melanoma and pulmonary metastases: factors predictive of survival. Annals of surgical oncology. 2007 Academic Article GET IT
Times cited: 76
Immunological validation of the EpitOptimizer program for streamlined design of heteroclitic epitopes. Vaccine. 2007 Academic Article GET IT
Times cited: 24
Surgical management of melanoma of the gallbladder: a report of 13 cases and review of the literature. American journal of surgery. 2007 Review GET IT
Times cited: 38
Current topics in melanoma. Current opinion in oncology. 2007 Review GET IT
Times cited: 22
Adjuvanticity of plasmid DNA encoding cytokines fused to immunoglobulin Fc domains. Clinical cancer research : an official journal of the American Association for Cancer Research. 2006 Academic Article GET IT
Times cited: 44
DNA immunization against tissue-restricted antigens enhances tumor immunity after allogeneic hemopoietic stem cell transplantation. Journal of immunology (Baltimore, Md. : 1950). 2006 Academic Article GET IT
Times cited: 16
DNA vaccines against cancer. Hematology/oncology clinics of North America. 2006 Review GET IT
Times cited: 18
Phase II study of temozolomide plus pegylated interferon-alpha-2b for metastatic melanoma. Cancer. 2006 Academic Article GET IT
Times cited: 46
Is tumor immunity the same thing as autoimmunity? Implications for cancer immunotherapy. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2006 Editorial Article GET IT
Times cited: 17
Agonist anti-GITR antibody enhances vaccine-induced CD8(+) T-cell responses and tumor immunity. Cancer research. 2006 Academic Article GET IT
Times cited: 177
Vaccination with human tyrosinase DNA induces antibody responses in dogs with advanced melanoma. Cancer immunity. 2006 Academic Article GET IT
Times cited: 126
Optimization of a self antigen for presentation of multiple epitopes in cancer immunity. The Journal of clinical investigation. 2006 Academic Article GET IT
Times cited: 78
Can we use monoclonal antibodies to help T cells fight tumors?. Cytotherapy. 2006 Comment GET IT
Cytokines in cytotherapy. Cytotherapy. 2006 Academic Article GET IT
In vitro expansion of Ag-specific T cells by HLA-A*0201-transfected K562 cells for immune monitoring. Cytotherapy. 2006 Academic Article GET IT
Times cited: 11
Unraveling the complex relationship between cancer immunity and autoimmunity: lessons from melanoma and vitiligo. Advances in immunology. 2006 Review GET IT
Times cited: 54
Comparison of two cancer vaccines targeting tyrosinase: plasmid DNA and recombinant alphavirus replicon particles. Clinical cancer research : an official journal of the American Association for Cancer Research. 2005 Academic Article GET IT
Times cited: 50
Dual mode reflectance and fluorescence confocal laser scanning microscopy for in vivo imaging melanoma progression in murine skin. The Journal of investigative dermatology. 2005 Academic Article GET IT
Times cited: 35
Induction of autoantibodies to syngeneic prostate-specific membrane antigen by xenogeneic vaccination. International journal of cancer. 2005 Academic Article GET IT
Times cited: 50
Development of a xenogeneic DNA vaccine program for canine malignant melanoma at the Animal Medical Center. Vaccine. 2005 Academic Article GET IT
Times cited: 223
Temozolomide plus thalidomide in patients with brain metastases from melanoma: a phase II study. Cancer. 2005 Academic Article GET IT
Times cited: 93
The role of the immune system in early epithelial carcinogenesis: B-ware the double-edged sword. Cancer cell. 2005 Comment GET IT
Times cited: 26
Antigens recognized by autologous antibodies of patients with soft tissue sarcoma. Cancer immunity. 2005 Academic Article GET IT
Times cited: 11
Identification of cancer-testis genes expressed by melanoma and soft tissue sarcoma using bioinformatics. Cancer immunity. 2005 Academic Article GET IT
Times cited: 35
CD8+ T-cell-dependent immunity following xenogeneic DNA immunization against CD20 in a tumor challenge model of B-cell lymphoma. Clinical cancer research : an official journal of the American Association for Cancer Research. 2005 Academic Article GET IT
Times cited: 30
DNA vaccines for melanoma. Cancer chemotherapy and biological response modifiers. 2005 Review GET IT
Times cited: 3
Persistence makes perfect: the benefits of IL-2 in adoptive immunotherapy. Cytotherapy. 2005 Comment GET IT
Times cited: 1
CD4 help and tumor immunity: beyond the activation of cytotoxic T lymphocytes. Annals of surgical oncology. 2004 Editorial Article GET IT
Times cited: 5
CTLA-4 blockade in combination with xenogeneic DNA vaccines enhances T-cell responses, tumor immunity and autoimmunity to self antigens in animal and cellular model systems. Vaccine. 2004 Academic Article GET IT
Times cited: 114
Tumor antigens for cancer immunotherapy: therapeutic potential of xenogeneic DNA vaccines. Journal of translational medicine. 2004 Academic Article GET IT
Times cited: 2409
Diffuse melanosis after chemotherapy-induced tumor lysis syndrome in a patient with metastatic melanoma. 2004 GET IT
Times cited: 29
Selective CD4+ lymphopenia in melanoma patients treated with temozolomide: a toxicity with therapeutic implications. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2004 Academic Article GET IT
Times cited: 227
Reassessing the usual suspects causing a commotion in the blood (and vessels?). Cancer biology & therapy. 2004 Comment GET IT
Times cited: 1
Consistent antibody response against ganglioside GD2 induced in patients with melanoma by a GD2 lactone-keyhole limpet hemocyanin conjugate vaccine plus immunological adjuvant QS-21. Clinical cancer research : an official journal of the American Association for Cancer Research. 2003 Academic Article GET IT
Times cited: 104
DNA vaccines: an active immunization strategy for prostate cancer. Seminars in oncology. 2003 Review GET IT
Times cited: 50
Phase II study of temozolomide plus thalidomide for the treatment of metastatic melanoma. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2003 Academic Article GET IT
Times cited: 137
Immunity to melanoma: unraveling the relation of tumor immunity and autoimmunity. Oncogene. 2003 Review GET IT
Times cited: 80
A single heteroclitic epitope determines cancer immunity after xenogeneic DNA immunization against a tumor differentiation antigen. Journal of immunology (Baltimore, Md. : 1950). 2003 Academic Article GET IT
Times cited: 92
Classification of clear-cell sarcoma as a subtype of melanoma by genomic profiling. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2003 Academic Article GET IT
Times cited: 165
Long-term survival of dogs with advanced malignant melanoma after DNA vaccination with xenogeneic human tyrosinase: a phase I trial. Clinical cancer research : an official journal of the American Association for Cancer Research. 2003 Academic Article GET IT
Times cited: 293
Phase I trial of high dose paracetamol and carmustine in patients with metastatic melanoma. Melanoma research. 2003 Academic Article GET IT
Times cited: 31
The role of lipopolysaccharide in T-cell responses following DNA vaccination. Vaccine. 2003 Academic Article GET IT
Times cited: 7
How can we tell when cancer vaccines vaccinate?. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2003 Editorial Article GET IT
Times cited: 8
Immunity to cancer through immune recognition of altered self: studies with melanoma. Advances in cancer research. 2003 Review GET IT
Times cited: 57
Multiple pathways to tumor immunity and concomitant autoimmunity. Immunological reviews. 2002 Review GET IT
Times cited: 69
Clinical results using biochemotherapy as a standard of care in advanced melanoma. Melanoma research. 2002 Academic Article GET IT
Times cited: 11
Induction of autoantibodies against tyrosinase-related proteins following DNA vaccination: unexpected reactivity to a protein paralogue. Cancer immunity. 2002 Academic Article GET IT
Phase I trial of adoptive immunotherapy with cytolytic T lymphocytes immunized against a tyrosinase epitope. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2002 Letter GET IT
Times cited: 5
Strategies to overcome immune ignorance and tolerance. Seminars in cancer biology. 2002 Review GET IT
Times cited: 43
GM-CSF DNA induces specific patterns of cytokines and chemokines in the skin: implications for DNA vaccines. Cytokines, cellular & molecular therapy. 2002 Academic Article GET IT
Times cited: 24
Melanoma vaccines. Cancer investigation. 2002 Review GET IT
Times cited: 16
Alternative roles for interferon-gamma in the immune response to DNA vaccines encoding related melanosomal antigens. Cancer immunity. 2001 Academic Article GET IT
Times cited: 11
Vaccines for melanoma: translating basic immunology into new therapies. The Lancet. Oncology. 2001 Review GET IT
Times cited: 41
Immunization with DNA coding for gp100 results in CD4 T-cell independent antitumor immunity. Surgery. 2000 Academic Article GET IT
Times cited: 85
Systemic chemotherapy. Clinics in plastic surgery. 2000 Review GET IT
Times cited: 14
Management of renal cell carcinoma. Oncology (Williston Park, N.Y.). 2000 Academic Article GET IT
Times cited: 17
Coupling and uncoupling of tumor immunity and autoimmunity. The Journal of experimental medicine. 1999 Academic Article GET IT
Times cited: 213
Injection of DNA encoding granulocyte-macrophage colony-stimulating factor recruits dendritic cells for immune adjuvant effects. Cytokines, cellular & molecular therapy. 1999 Academic Article GET IT
Times cited: 54
Prophylactic recombinant epoetin alfa markedly reduces the need for blood transfusion in patients with metastatic melanoma treated with biochemotherapy. Cytokines, cellular & molecular therapy. 1999 Academic Article GET IT
Times cited: 8
Tumor immunity and autoimmunity induced by immunization with homologous DNA. The Journal of clinical investigation. 1998 Academic Article GET IT
Times cited: 202
Vaccines and other adjuvant therapies for melanoma. Hematology/oncology clinics of North America. 1998 Review GET IT
Times cited: 13
Localized squamous cell carcinoma of the bladder causing hypercalcemia and inhibition of PTH secretion. 1998 GET IT
Times cited: 10
Treatment of Behçet disease with pentoxifylline. Annals of internal medicine. 1997 Letter GET IT
Times cited: 4
Melanocyte differentiation marker gp75, the brown locus protein, can be regulated independently of tyrosinase and pigmentation. The Journal of investigative dermatology. 1995 Academic Article GET IT
Times cited: 32
Activation of NF-kappa B may be necessary but is not sufficient for induction of H-2 antigens by TNF in J558L murine myeloma cells. Journal of leukocyte biology. 1994 Academic Article GET IT
Times cited: 5
Induction of HLA class I mRNA by cytokines in human fibroblasts: comparison of TNF, IL-1 and IFN-beta. Cytokine. 1992 Academic Article GET IT
Times cited: 8
Critical role of a common transcription factor, IRF-1, in the regulation of IFN-beta and IFN-inducible genes. The EMBO journal. 1992 Academic Article GET IT
Times cited: 222
There is more to hemorrhagic necrosis than tumor necrosis factor. Journal of the National Cancer Institute. 1991 Editorial Article GET IT
Times cited: 1

more ...

less ...

Research

Sort by

Co-investigator Network

Funding awarded

Ludwig Collaborative Laboratory awarded by Ludwig Institute for Cancer Research Principal Investigator 2022 - 2027
DNA Vaccines Against Cancer and Infectious Organisms awarded by Breast Cancer Research Foundation, Inc. Principal Investigator 2022 - 2023

Proteogenomic studies to understand mechanisms and drivers of resistance to immunotherapies awarded by National Cancer Institute Principal Investigator Subaward 2022 - 2027
MSK Immuno-Oncology for the Translational Researcher Short Course awarded by National Institute of Diabetes & Digestive & Kidney Diseases Principal Investigator Subaward 2022 - 2024

more ...

less ...

Background

education and training

M.D., New York University School of Medicine 1994
Ph.D., New York University 1993
M.S., New York University 1991
B.A., Princeton University 1987

Contact

full name

Jedd D Wolchok

primary email

jdw2002@med.cornell.edu

webpage

Clinical Profile

VIVO Weill Cornell Medical College

Jedd D Wolchok Meyer Cancer Center Director

Publications

selected publications

Research

Funding awarded

Background

education and training

Contact

full name

primary email

webpage